Final results of a phase I trial of oral vorinostat (Suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma

被引：5
|
作者：
Richardson, Paul G. [1 ]
Mitsiades, Constantine S. [1 ]
Colson, Kathleen [1 ]
Reilly, Eileen [2 ]
McBride, Laura [2 ]
Chiao, Judy
Sun, Linda
Ricker, Justin L. [3 ]
Rizvi, Syed [3 ]
Oerth, Carol [3 ]
Atkins, Barbara [3 ]
Fearen, Ivy
Anderson, Kenneth C. [1 ]
Siegel, David S. [2 ]
机构：
[1] Harvard Med Sch, Dana Farber Canc Inst, Boston, MA USA
[2] Hackensack Univ, Med Ctr, Ctr Canc, Hackensack, NJ USA
[3] Merck Res Labs, Upper Gwynedd, PA USA
来源：
BLOOD | 2007年 / 110卷 / 11期
关键词：
D O I：
10.1182/blood.V110.11.1179.1179
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1179
引用
收藏
页码：357A / 357A
页数：1
相关论文
共 50 条
  • [21] Phase II trial of oral suberoylanilide hydroxamic acid (SAHA) for cutaneous T-cell lymphomas
    Talpur, R
    Chiao, N
    Richon, V
    Chiao, JH
    Duvic, M
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2004, 122 (03) : A53 - A53
  • [22] Phase I study of oral suberoylanilide hydroxamic acid (SAHA), a histone deacetylase inhibitor, in patients (pts) with advanced leukemias or myelodysplastic syndromes (MDS)
    Garcia-Manero, G
    Issa, JP
    Cortes, J
    Koller, C
    O'brien, S
    Estey, E
    Canalli, AA
    Chiao, J
    Richon, V
    Kantarjian, H
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 201S - 201S
  • [23] Vorinostat (Suberoylanilide hydroxamic acid, SAHA) provides prolonged clinical benefit to advanced cutaneous T-Cell lymphoma patients: Updated results of the phase IIb multicenter clinical trial.
    Duvic, Madeleine
    Kim, Youn H.
    Kuzel, Timothy M.
    Pacheco, Theresa R.
    Foss, Francine M.
    Parker, Sareeta
    Frankel, Stanley R.
    Chen, Cong
    Ricker, Justin L.
    Arduino, Jean Marie
    Randolph, Sophia
    Richon, Victoria M.
    Olsen, Elise A.
    BLOOD, 2006, 108 (11) : 122A - 122A
  • [24] Phase II trial of the histone deacetylase inhibitor vorinostat (Zolinza™, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or metastatic head and neck cancer
    George R. Blumenschein
    Merrill S. Kies
    Vassiliki A. Papadimitrakopoulou
    Charles Lu
    Ashok J. Kumar
    Justin L. Ricker
    Judy H. Chiao
    Cong Chen
    Stanley R. Frankel
    Investigational New Drugs, 2008, 26 : 81 - 87
  • [25] Phase II trial of the histone deacetylase inhibitor vorinostat (Zolinza™, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or metastatic head and neck cancer
    Blumenschein, George R., Jr.
    Kies, Merrill S.
    Papadimitrakopoulou, Vassiliki A.
    Lu, Charles
    Kumar, Ashok J.
    Ricker, Justin L.
    Chiao, Judy H.
    Chen, Cong
    Frankel, Stanley R.
    INVESTIGATIONAL NEW DRUGS, 2008, 26 (01) : 81 - 87
  • [26] Phase I and pharmacokinetic study of vorinostat (suberoylanilide hydroxamic acid) in Japanese patients with solid tumors
    Fujiwara, Yutaka
    Yamamoto, Noboru
    Yamada, Yasuhide
    Yamada, Kazuhiko
    Otsuki, Tetsuya
    Kanazu, Shinichi
    Iwasa, Takashi
    Hardwick, James S.
    Tamura, Tomohide
    CANCER SCIENCE, 2009, 100 (09): : 1728 - 1734
  • [27] NCI 6896: A phase I trial of suberoylanilide hydroxamic acid (SAHA) and 13-cis retinoic acid in the treatment of patients with advanced renal cell carcinoma
    Nanus, D. M.
    Tagawa, S. T.
    Dutcher, J. P.
    Akhtar, N. H.
    Saran, A.
    Mazumdar, M.
    Milowsky, M. I.
    Gudas, L. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (07)
  • [28] Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer
    Kelly, WK
    O'Connor, OA
    Krug, LM
    Chiao, JH
    Heaney, M
    Curley, T
    MacGregore-Cortelli, B
    Tong, W
    Secrist, JP
    Schwartz, L
    Richardson, S
    Chu, E
    Olgac, S
    Marks, PA
    Scher, H
    Richon, VM
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (17) : 3923 - 3931
  • [29] Phase I study of vorinostat (suberoylanilide hydroxamic acid, NSC 701852) in combination with docetaxel in patients with advanced and relapsed solid malignancies
    Schneider, Bryan J.
    Kalemkerian, Gregory P.
    Bradley, Deborah
    Smith, David C.
    Egorin, Merrill J.
    Daignault, Stephanie
    Dunn, Rodney
    Hussain, Maha
    INVESTIGATIONAL NEW DRUGS, 2012, 30 (01) : 249 - 257
  • [30] Phase I study of vorinostat (suberoylanilide hydroxamic acid, NSC 701852) in combination with docetaxel in patients with advanced and relapsed solid malignancies
    Bryan J. Schneider
    Gregory P. Kalemkerian
    Deborah Bradley
    David C. Smith
    Merrill J. Egorin
    Stephanie Daignault
    Rodney Dunn
    Maha Hussain
    Investigational New Drugs, 2012, 30 : 249 - 257
12345